Regulation of the Bcas1 and Baiap3 transcripts in the subthalamic nucleus in mice recovering from MPTP toxicity

Neuroscience Research

Volumn 70, Issue 3, 2011, Pages 269-276

  Lauridsen, J B ^a,b   Johansen, J L ^b   Rekling, J C ^a   Thirstrup, K ^b   Moerk, A ^b   Sager, T N ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

Baiap3; Bcas1; Laser dissection; Microarray; MPTP; Nest building; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN SPECIFIC ANGIOGENESIS INHIBITOR ASSOCIATED PROTEIN 3; BREAST CARCINOMA AMPLIFIED SEQUENCE 1 PROTEIN; GENE PRODUCT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SUBTHALAMIC NUCLEUS; SYMPTOM;

EID: 79957606700     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2011.03.011     Document Type: Article

References (55)

1. Aberg K., Saetre P., Jareborg N., Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(19):7482-7487.
2. Aberg K., Saetre P., Lindholm E., Ekholm B., Pettersson U., Adolfsson R., Jazin E. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141B(1):84-90.
3. Allen Institute for Brain Science S. W., 2010. Allen Mouse Brain Atlas at http://mouse.brain-map.org/.
4. Appay V, Bosio A., Lokan S., Wiencek Y., Biervert C., Kusters D., Devevre E., Speiser D., Romero P., Rufer N., Leyvraz S. Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. J. Immunol. 2007, 179(11):7406-7414.
5. Baunez C., Nieoullon A., Amalric M. In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit. J. Neurosci. 1995, 15(10):6531-6541.
6. Beardsley D.I., Kowbel D., Lataxes T.A., Mannino J.M., Xin H., Kim W.J., Collins C., Brown K.D. Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Exp. Cell Res. 2003, 290(2):402-413.
7. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 1994, 72(2):507-520.
8. BioGPS, 2010. Gene Atlas expression profiles, Genomics Institute of the Novartis Research Foundation at http://biogps.gnf.org/.
9. Brose N., Hofmann K., Hata Y., Sudhof T.C. Mammalian homologues of Caenorhabditis elegans unc-13 gene define novel family of C2-domain proteins. J. Biol. Chem. 1995, 270(42):25273-25280.
10. Brose N., Rosenmund C., Rettig J. Regulation of transmitter release by Unc-13 and its homologues. Curr. Opin. Neurobiol. 2000, 10(3):303-311.
11. Burmester J.K., Suarez B.K., Lin J.H., Jin C.H., Miller R.D., Zhang K.Q., Salzman S.A., Reding D.J., Catalona W.J. Analysis of candidate genes for prostate cancer. Hum. Hered. 2004, 57(4):172-178.
12. Chin M.H., Qian W.J., Wang H., Petyuk V.A., Bloom J.S., Sforza D.M., Lacan G., Liu D., Khan A.H., Cantor R.M., Bigelow D.J., Melega W.P., Camp D.G., Smith R.D., Smith D.J. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J. Proteome Res. 2008, 7(2):666-677.
13. Collins C., Rommens J.M., Kowbel D., Godfrey T., Tanner M., Hwang S.I., Polikoff D., Nonet G., Cochran J., Myambo K., Jay K.E., Froula J., Cloutier T., Kuo W.L., Yaswen P., Dairkee S., Giovanola J., Hutchinson G.B., Isola J., Kallioniemi O.P., Palazzolo M., Martin C., Ericsson C., Pinkel D., Albertson D., Li W.B., Gray J.W. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(15):8703-8708.
14. Correa R.G., de Carvalho A.F., Pinheiro N.A., Simpson A.J., de Souza S.J. NABC1 (BCAS1): alternative splicing and downregulation in colorectal tumors. Genomics 2000, 65(3):299-302.
15. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909.
16. During M.J., Kaplitt M.G., Stern M.B., Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 2001, 12(12):1589-1591.
17. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J. 2007, 48(4):339-355.
18. Emborg M.E., Carbon M., Holden J.E., During M.J., Ma Y., Tang C., Moirano J., Fitzsimons H., Roitberg B.Z., Tuccar E., Roberts A., Kaplitt M.G., Eidelberg D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab. 2007, 27(3):501-509.
19. Feng W., Wei H., Liu G.T. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol. Neurobiol. 2005, 31(1-3):295-300.
20. Ferrara J.M., Diamond A., Hunter C., Davidson A., Almaguer M., Jankovic J. Impact of STN-DBS on Life and Health Satisfaction in Patients with Parkinson Disease. J. Neurol. Neurosurg. Psychiatry 2009, 81(3):315-319.
21. Garcia L., D'Alessandro G., Fernagut P.O., Bioulac B., Hammond C. Impact of high-frequency stimulation parameters on the pattern of discharge of subthalamic neurons. J. Neurophysiol. 2005, 94(6):3662-3669.
22. Guridi J., Herrero M.T., Luquin M.R., Guillen J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., Obeso J.A. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996, 119(5):1717-1727.
23. Hofele K., Sedelis M., Auburger G.W., Morgan S., Huston J.P., Schwarting R.K. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp. Neurol. 2001, 168(1):116-122.
24. Huston J.P., Nef B., Papadopoulos G., Welzl H. Activation and lateralization of sensorimotor field for perioral biting reflex by intranigral GABA agonist and by systemic apomorphine in the rat. Brain Res. Bull. 1980, 5(6):745-749.
25. Kim J.M., Lee K.H., Jeon Y.J., Oh J.H., Jeong S.Y., Song I.S., Kim J.M., Lee D.S., Kim N.S. Identification of genes related to Parkinson's disease using expressed sequence tags. DNA Res. 2006, 13(6):275-286.
26. Kirchhoff J., Mork A., Brennum L.T., Sager T.N. Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice. Neuroreport 2009, 20(5):482-486.
27. Lauriat T.L., Shiue L., Haroutunian V., Verbitsky M., Ares M., Ospina L., McInnes L.A. Developmental expression profile of quaking, a candidate gene for schizophrenia, and its target genes in human prefrontal cortex and hippocampus shows regional specificity. J. Neurosci. Res. 2008, 86(4):785-796.
28. Lein E.S., Hawrylycz M.J., Ao N., Ayres M., Bensinger A., Bernard A., Boe A.F., Boguski M.S., Brockway K.S., Byrnes E.J., Chen L., Chen L., Chen T.M., Chin M.C., Chong J., Crook B.E., Czaplinska A., Dang C.N., Datta S., Dee N.R., Desaki A.L., Desta T., Diep E., Dolbeare T.A., Donelan M.J., Dong H.W., Dougherty J.G., Duncan B.J., Ebbert A.J., Eichele G., Estin L.K., Faber C., Facer B.A., Fields R., Fischer S.R., Fliss T.P., Frensley C., Gates S.N., Glattfelder K.J., Halverson K.R., Hart M.R., Hohmann J.G., Howell M.P., Jeung D.P., Johnson R.A., Karr P.T., Kawal R., Kidney J.M., Knapik R.H., Kuan C.L., Lake J.H., Laramee A.R., Larsen K.D., Lau C., Lemon T.A., Liang A.J., Liu Y., Luong L.T., Michaels J., Morgan J.J., Morgan R.J., Mortrud M.T., Mosqueda N.F., Ng L.L., Ng R., Orta G.J., Overly C.C., Pak T.H., Parry S.E., Pathak S.D., Pearson O.C., Puchalski R.B., Riley Z.L., Rockett H.R., Rowland S.A., Royall J.J., Ruiz M.J., Sarno N.R., Schaffnit K., Shapovalova N.V., Sivisay T., Slaughterbeck C.R., Smith S.C., Smith K.A., Smith B.I., Sodt A.J., Stewart N.N., Stumpf K.R., Sunkin S.M., Sutram M., Tam A., Teemer C.D., Thaller C., Thompson C.L., Varnam L.R., Visel A., Whitlock R.M., Wohnoutka P.E., Wolkey C.K., Wong V.Y., Wood M., Yaylaoglu M.B., Young R.C., Youngstrom B.L., Yuan X.F., Zhang B., Zwingman T.A., Jones A.R. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007, 445(7124):168-176.
29. Lindholm E., Aberg K., Ekholm B., Pettersson U., Adolfsson R., Jazin E.E. Reconstruction of ancestral haplotypes in a 12-generation schizophrenia pedigree. Psychiatr. Genet. 2004, 14(1):1-8.
30. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., Sherrington R., Adolfsson R., Jazin E. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am. J. Hum. Genet. 2001, 69(1):96-105.
31. Luchtman D.W., Shao D., Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 2009, 98(1-2):130-138.
32. Mandel S., Grunblatt E., Maor G., Youdim M.B. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 2002, 27(10):1231-1243.
33. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., Kaysser-Kranich T.M., Sendera T.J., Palaniappan C., Federoff H.J. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 2004, 24(34):7445-7454.
34. Morissette M., Al S.S., Callier S., Di P.T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol. Cell. Endocrinol. 2008, 290(1-2):60-69.
35. Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O. Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1998, 5(5):277-286.
36. Nishi K., Kondo T., Narabayashi H. Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice. Brain Res. 1989, 489(1):157-162.
37. Nishimori H., Shiratsuchi T., Urano T., Kimura Y., Kiyono K., Tatsumi K., Yoshida S., Ono M., Kuwano M., Nakamura Y., Tokino T. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997, 15(18):2145-2150.
38. Noveroske J.K., Hardy R., Dapper J.D., Vogel H., Justice M.J. A new ENU-induced allele of mouse quaking causes severe CNS dysmyelination. Mamm. Genome 2005, 16(9):672-682.
39. Orita S., Naito A., Sakaguchi G., Maeda M., Igarashi H., Sasaki T., Takai Y. Physical and functional interactions of Doc2 and Munc13 in Ca2+-dependent exocytotic machinery. J. Biol. Chem. 1997, 272(26):16081-16084.
40. Palmer R.E., Lee S.B., Wong J.C., Reynolds P.A., Zhang H., Truong V., Oliner J.D., Gerald W.L., Haber D.A. Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell 2002, 2(6):497-505.
41. Parkin S., Nandi D., Giladi N., Joint C., Gregory R., Bain P., Scott R., Aziz T.Z. Lesioning the subthalamic nucleus in the treatment of Parkinson's disease. Stereotact. Funct. Neurosurg. 2001, 77(1-4):68-72.
42. Pattarini R., Rong Y., Qu C., Morgan J.I. Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum. Neuroscience 2008, 155(4):1174-1194.
43. Paulsen S.J., Larsen L.K., Jelsing J., Janssen U., Gerstmayer B., Vrang N. Gene expression profiling of individual hypothalamic nuclei from single animals using laser capture microdissection and microarrays. J. Neurosci. Methods 2009, 177(1):87-93.
44. Ross C.A., Smith W.W. Gene-environment interactions in Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl. 3):S309-S315.
45. Sager T.N., Kirchhoff J., Mork A., Van B.J., Thirstrup K., Didriksen M., Lauridsen J.B. Nest building performance following MPTP toxicity in mice. Behav. Brain Res. 2010, 208(2):444-449.
46. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., Lightfoot S., Menzel W., Granzow M., Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 2006, 7(3):1-14.
47. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 2000, 30(3):171-182.
48. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 2001, 125(1-2):109-125.
49. Shiratsuchi T., Oda K., Nishimori H., Suzuki M., Takahashi E., Tokino T., Nakamura Y. Cloning and characterization of BAP3 (BAI-associated protein 3), a C2 domain-containing protein that interacts with BAI1. Biochem. Biophys. Res. Commun. 1998, 251(1):158-165.
50. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134(1):57-66.
51. Upchurch M., Schallert T. A behavior analysis of the offspring of " haloperidol-sensitive" and " haloperidol-resistant" gerbils. Behav. Neural Biol. 1983, 39(2):221-228.
52. Vandesompele J., De P.K., Pattyn F., Poppe B., Van R.N., De P.A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3(7):1-12.
53. Wichmann T., DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. NY Acad. Sci. 2003, 991:199-213.
54. Wick P.F., Senter R.A., Parsels L.A., Uhler M.D., Holz R.W. Transient transfection studies of secretion in bovine chromaffin cells and PC12 cells. Generation of kainate-sensitive chromaffin cells. J. Biol. Chem. 1993, 268(15):10983-10989.
55. Youdim M.B., Grunblatt E., Levites Y., Maor G., Mandel S. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. Neurotox Res. 2002, 4(7-8):679-689.